Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 3/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16042310 | 0.88 | CHRM2 (0.34) | CHRM2CHRM4CHRM1HRH3CHRM5 | |
| SCHEMBL121604 | 0.84 | L3MBTL3 (0.34) | HRH3KCNH2L3MBTL3L3MBTL1 | |
| SCHEMBL1799606 | 0.83 | SMN1; SMN2 (0.46) | CHRM2CHRM4CHRM1HRH3SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL3665053 | 0.81 | L3MBTL3 (0.33) | HRH3KCNH2SMN1; SMN2L3MBTL3L3MBTL1 | |
| SCHEMBL6628090 | 0.79 | OPRM1 (0.43) | HRH3L3MBTL3L3MBTL1 | |
| SCHEMBL4213726 | 0.79 | MAPK1 (0.43) | HRH3L3MBTL3L3MBTL1 | |
| SCHEMBL7633925 | 0.77 | OPRM1 (0.46) | HRH3 | |
| SCHEMBL551401 | 0.77 | OPRM1 (0.46) | HRH3 | |
| SCHEMBL21047675 | 0.77 | OPRM1 (0.46) | HRH3 | |
| SCHEMBL1181799 | 0.77 | OPRM1 (0.46) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250114374-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2025-04-10 | — | — | US | disclosed |
| WO-2023122000-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. (US) | 2023-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250114374-A1 | BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L10 | CHRM2 1651/4885CHRM4 3003/4885CHRM1 2442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.